logo
  

Stock Alert: SAP Tumbles 21% After Cutting FY20 Revenue Outlook

Shares of SAP SE (SAP) are falling more than 21 percent or $32.26 in Monday's morning trade at $117.42 after the German software major lowered its revenue forecast for fiscal 2020.

For fiscal 2020, SAP now expects non-IFRS total revenue to be 27.2 billion euros to 27.8 billion euros at constant currencies, compared to its prior outlook of 27.8 billion euros to 28.5 billion euros. The company expects the COVID-19 pandemic to impact the demand environment through at least the first half of 2021, pushing out the achievement of key metrics such as non-IFRS cloud revenue, total revenue, and operating profit, by 1 to 2 years.

SAP reported that its third-quarter profit after tax rose 31 percent to 1.65 billion euros from last year's 1.26 billion euros. Earnings per basic share rose 26 percent year over year to 1.32 euros on a IFRS basis and also increased 31 percent to 1.70 euros on a non-IFRS basis. Total revenue declined 4 percent from last year to 6.54 billion euros.

SAP has traded in a range of $90.90 to $169.30 in the past 52 weeks.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT